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Chronic heart failure is one of the most important geriatric syndromes, associated with
disability, increased hospital admissions, and high mortality. The aim of this study was to
evaluate the existence of age-related differences in clinical effectiveness and outcomes of
cardiac resynchronization therapy (CRT), alone or in combination with an implantable
cardioverter-defibrillator (CRT-D), in a large, real-world registry. A total of 1,787 patients
admitted for CRT or CRT-D to the 117 centers participating in the InSync/InSync ICD
Italian Registry from 1999 to 2005 were evaluated. Patients were divided into 3 age groups:
<65 years (n 571), 65 to 74 years (n 740), and>75 years (n 476). The left ventricular
ejection fraction did not differ in the 3 groups (26 8% vs 26 7% vs 27 8%, p 0.123).
Atrial fibrillation prevalence demonstrated an age-related increase. The use of recom-
mended medical therapy for chronic heart failure decreased with age, as well as CRT-D
implantation (p <0.001). The percentage of echocardiographic responders to CRT was
similar in the 3 groups, and New York Heart Association class significantly improved
independent of age. During the follow-up period (19  13 months), all-cause mortality was
higher in patients aged >75 years than in those aged <65 years (p  0.005). In the whole
population, mortality was associated with the nonresponder condition, the presence of
atrial fibrillation and the lack of prescription of recommended medical therapy. In con-
clusion, CRT improved left ventricular performance and functional capacity independent
of age. The proportion of the responder condition to CRT was the same in all groups.
Pharmacologic undertreatment is an important issue in a “real-world” geriatric
population. © 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:1510–1516)
c
t
gDespite the relevant increase in the prevalence and in the
incidence of chronic heart failure (CHF) in older individu-
als, the mean age of patients enrolled in clinical trials of
cardiac resynchronization therapy (CRT) is 70 years.1–4
Thus, at present, there is no trial-derived specific informa-
tion on the impact of CRT in subjects of advanced age.
Observational data, obtained from clinical registries, may
provide a useful insight into “real-world” CRT. Conse-
quently, through analysis of the InSync/InSync ICD Italian
Registry, a large database involving 117 Italian centers, we
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doi:10.1016/j.amjcard.2011.01.031aimed to evaluate the existence of age-related differences in
clinical and instrumental effectiveness (the primary end
point) and long-term mortality (the secondary end point)
during CRT, alone or in combination with an implantable
cardioverter-defibrillator (CRT-D).
Methods
From 1999 to 2005, all 1,787 patients successfully im-
planted with biventricular pacing devices for CRT or
CRT-D (Medtronic Inc., Minneapolis, Minnesota) were
prospectively included in the InSync/InSync ICD Ital-
ian Registry. The registry enrolled patients with advan-
ced symptomatic CHF, left ventricular ejection fraction
(LVEF) 35%, and wide QRS complexe (130 ms).5 Ac-
ording to protocol, CRT or CRT-D should have been added
o optimal medical therapy as recommended by the current
uidelines for the diagnosis and treatment of CHF.6 The
protocol of the InSync/InSync ICD Italian Registry, which
complies with the Declaration of Helsinki, had been previ-
ously approved by the ethics committees of each participat-
ing center. At the time of enrollment, all patients gave their
written informed consent to participate to the study. For
each patient, demographic, history, and clinical variables
were collected at baseline, before device implantation. The
www.ajconline.org
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1511Heart Failure/CRT in Elderly Patientspresence of chronic obstructive pulmonary disease, diabe-
tes, hypertension, and renal failure was ascertained ac-
cording to current guidelines.7–10 The stage of CHF was
ssessed according to New York Heart Association func-
ional classification.11 Moreover, the number of hospitaliza-
ions due to CHF in the preceding 12 months was reported
n the database. According to the design of the present
tudy, we introduced only 2 variables to the original data
et, the first associated with the presence of 2 co-morbid
onditions in the same subject and the second for the age
tratification of the population, which was consequently
ivided into 3 groups: 65, 65 to 74, and 75 years.
The echocardiographic evaluation of a patient was per-
ormed as previously reported.12 At all centers, all exami-
ations of a subject were always made by the same physi-
ian, who had a specific competence in assessing the effects
f CRT. Interventricular mechanical delay (the time interval
etween the onset of anterograde blood flow in the right and
n the left ventricular outflow tracts) was used as the indi-
ator of interventricular dyssynchrony.13 Optimization of
CRT was recommended through echocardiography-guided
programming of atrioventricular delay.12
All patients underwent standard clinical visits at 1, 3, and
6 months and every 6 months thereafter; the study charts
were always compiled by the physicians operating at the
electrophysiology center. By protocol, a complete clinical
Table 1
Clinical and instrumental characteristics of the InSync/InSync ICD Italian
Variable
Age (years)
Men
hronic obstructive pulmonary disease
iabetes mellitus
ypertension
enal failure
3 co-morbidities
oronary artery disease
V end-diastolic diameter (mm)
V end-systolic diameter (mm)
V end-diastolic volume (ml)
LV end-systolic volume (ml)
LVEF (%)
QRS length (ms)
New York Heart Association class
Hospitalizations (n)
Permanent AF
Atrioventricular node ablation
Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
 blockers
igoxin
iuretics
itrates
lass III antiarrhythmic drugs
Data are expressed as mean  SD or as number (percentage).
LV  left ventricular.
* p 0.05 vs 65 years.
† p 0.05 vs 65 to 74 years.and instrumental reassessment was performed at least 6 and C12 months after the implantation of the device. At 17 and 33
months, entire evaluations were available for 836 (47%) and
296 (17%) subjects of the original cohort. Patients showing
reductions of left ventricular end-systolic volume 10% at
the 6-month follow-up visit were defined as responders to
CRT.12,14 For the purposes of this study, we reported only
the results of the 6- and 12-month clinical and instrumental
evaluations of patients. However, mortality data are related
to the entire length of follow-up.
Statistical analysis was performed using SPSS for Win-
dows version 18.0 (SPSS Inc., Chicago, Illinois). All anal-
yses were carried out in the statistical laboratory of
Medtronic Italy (Milan, Italy) on proposal of the chief
investigators of the study. Continuous variables are ex-
pressed as mean  SD. Categorical variables are expressed
s percentages. Comparisons between groups of patients
ere performed using analysis of variance or chi-square
ests for continuous or categorical variables, respectively.
hanges in clinical and instrumental parameters during fol-
ow-up were evaluated using analysis of variance for re-
eated measures. Post hoc tests were applied to assess the
xistence of significant differences between each point of
he follow-up and the baseline value.
All-cause mortality was studied using Kaplan-Meier
urves and Cox regression analysis in univariate models. All
ignificant clinical predictors were further introduced in a
ry population
Age Group (years) p Value
65
(n  571)
65–74
(n  740)
75
(n  476)
57  7 70  3 78  3 —
481 (84%) 603 (81%) 362 (76%)*† 0.003
26 (5%) 55 (7%)* 27 (6%) 0.088
47 (8%) 64 (9%) 30 (6%) 0.312
73 (13%) 133 (18%)* 97 (20%)* 0.003
18 (3%) 58 (8%)* 21 (4%)† 0.001
24 (4%) 68 (9%)* 34 (7%)* 0.002
223 (39%) 367 (50%)* 240 (50%)* 0.001
70  10 69  9 68  9* 0.015
60  12 58  10 57  11* 0.016
242  94 221  91 209  104* 0.050
168  81 154  85 133  63* 0.025
26  8 26  7 27  8 0.123
167  33 165  31 162  32 0.136
2.9  0.6 3.0  0.6 3.0  0.6* 0.063
1.6  1.4 1.6  1.5 1.7  1.4 0.256
61 (11%) 131 (18%)* 101 (21%)* 0.001
28 (5%) 67 (9%)* 32 (7%) 0.014
450 (79%) 525 (71%)* 335 (70%)* 0.001
341 (60%) 331 (45%)* 176 (37%)*† 0.001
244 (43%) 316 (43%) 216 (45%) 0.604
494 (87%) 658 (89%) 419 (88%) 0.415
96 (17%) 169 (23%)* 126 (26%)* 0.001
193 (34%) 278 (38%) 164 (34%) 0.312Registox multivariate regression model. In case of colinearity,
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1512 The American Journal of Cardiology (www.ajconline.org)only the variable that was more tightly associated with
mortality was used. The results are reported also as hazard
ratios with their related 95% confidence intervals. Assessing
the influence of age on survival, the reference level (hazard
ratio 1) was attributed to the group aged 65 years. For all
analyses, a 2-tailed p value 0.05 was considered to indi-
cate statistical significance.
Results
From 1999 to 2005, as previously mentioned, 1,787
consecutive subjects were enrolled in the InSync/InSync
ICD Italian Registry. The oldest patients represented 27%
(n  476) of the entire cohort; the percentage of women
significantly increased with age (Table 1). Coronary artery
disease, hypertension, and the coexistence of 3 co-morbid
conditions were most represented in the 2 oldest groups.
Baseline left ventricular diameters and volumes signifi-
cantly decreased in an age-related fashion, while interven-
tricular mechanical delay did not differ at all (Table 1). The
prevalence of atrial fibrillation (AF) was significantly higher
in patients aged 65 years. The use of angiotensin-convert-
ing enzyme inhibitors and angiotensin receptor blockers and
of  blockers significantly decreased with age (Table 1).
Table 2
Changes in left ventricular geometry and performance at the 6- and the 1
Variable
Baseline
V end-diastolic diameter (mm)
65 years 70  10
65–74 years 69  9
75 years 68  9
LV end-systolic diameter (mm)
65 years 60  12
65–74 years 58  10
75 years 57  11
LV end-diastolic volume (ml)
65 years 242  94
65–74 years 221  91
75 years 209  104
LV end-systolic volume (ml)
65 years 168  81
65–74 years 154  85
75 years 133  63
LVEF (%)
65 years 26  8
65–74 years 26  7
75 years 27  8
Interventricular mechanical delay (ms)
65 years 38  44
65–74 years 44  28
75 years 39  34
Data are expressed as mean  SD.
LV  left ventricular.
* The p value for the whole trend in each age-group.
† The p value exploring the interaction between each parameter trend and
the follow-up).
‡ p 0.001 vs baseline.
§ p 0.05 vs baseline.RT-D was progressively less often adopted with advanc- 5ng age (65 years, 48%; 65 to 74 years, 43%; 75 years,
9%; p 0.001).
CRT produced significant and similar left ventricular
everse remodeling in the 3 age groups (Table 2), which
howed the same prevalence of responders (65 years,
Figure 1. CRT-induced changes in New York Heart Association (NYHA)
class between baseline and the 12-month evaluation, by age group.
follow-up evaluations
y Phase p Value* p Value†
6
onths
12
Months
 12‡ 66  12‡ 0.001
 10‡ 66  11‡ 0.001 0.131
 10‡ 64  10‡ 0.001
 13‡ 54  13‡ 0.001
 12‡ 53  13‡ 0.001 0.251
 12‡ 51  13‡ 0.001
 91 191  89§ 0.001
 74§ 180  74§ 0.001 0.197
 64 158  65 0.008
 77§ 125  76§ 0.001
 61‡ 120  63§ 0.001 0.365
 60 100  60 0.001
 10‡ 34  11‡ 0.001
 11‡ 34  11‡ 0.001 0.830
 11‡ 37  12‡ 0.001
 29‡ 22  26‡ 0.001
 25‡ 20  26‡ 0.001 0.841
 25‡ 13  23‡ 0.001
oups (p values 0.05 indicate behaviors not different by age group during2-month
Stud
M
67
66
64
54
54
52
192
181
158
126
121
102
34
33
36
22
18
14
age gr8%; 65 to 74 years, 60%; 75 years, 62%; p  0.419).
m
8
C
m

d
e
T
R
b
m
C
C
1513Heart Failure/CRT in Elderly PatientsCRT significantly improved functional capacity indepen-
dent of age (Figure 1).
After 12 months, the proportion of patients with 1
readmission for CHF was not statistically different among
the 3 groups (65 years, 10%; 65 to 74 years, 12%; 75
years, 13%; p  0.509).
At the end of the follow-up period (mean 19  13
onths), all-cause mortality was 10% (n  60), 12% (n 
6), and 14% (n  65) in patients aged 65, 65 to 74, and
75 years, respectively. Kaplan-Meier analysis revealed a
Figure 2. Kaplan-Meier analysis of overall survival in the InSync popula-
tion by age group. Only the comparison between the trends observed in
patients aged 75 and 65 years showed a statistically significant differ-
nce.
able 3
esults of univariate Cox regression analyses exploring the association
etween clinical and instrumental variables and all-cause follow-up
ortality in the entire InSync/InSync ICD Italian Registry population
Variable HR 95% CI p Value
Age group (years)
65 1
65–74 0.99 0.76–1.31 0.976
75 1.47 1.10–1.98 0.010
Men vs women 1.67 1.12–2.49 0.012
Chronic obstructive pulmonary disease
( vs )
1.53 0.90–2.60 0.113
Diabetes mellitus ( vs ) 0.93 0.55–1.57 0.775
Hypertension ( vs ) 1.14 0.80–1.62 0.483
Renal failure ( vs ) 1.94 1.24–3.05 0.004
3 co-morbidities ( vs ) 1.75 1.13–2.73 0.013
Coronary artery disease ( vs ) 1.34 1.02–1.76 0.033
LV end-diastolic diameter (mm) 1.01 0.99–1.02 0.592
LV end-systolic diameter (mm) 1.01 0.98–1.02 0.887
LVEF (%) 0.98 0.96–0.99 0.025
QRS length (ms) 1.00 0.99–1.01 0.605
New York Heart Association class 1.07 0.84–1.36 0.596
Permanent atrial fibrillation ( vs ) 1.62 1.18–2.22 0.003
Atrioventricular node ablation ( vs ) 0.96 0.57–1.63 0.890
Angiotensin-converting enzyme
inhibitors/angiotensin receptor
blockers ( vs )
0.64 0.48–0.85 0.002
 blockers ( vs ) 0.46 0.35–0.62 0.001
RT responder ( vs ) 0.40 0.30–0.52 0.001
RT-D ( vs ) 0.94 0.70–1.25 0.664
CI  confidence interval; HR  hazard ratio; LV  left ventricular.lower survival rate in the oldest group compared to the uyoungest group (Figure 2). Among patients with known
causes of mortality (n  177/211 [84%]), no age-related
differences in sudden (65 years, 2.3%; 65 to 74 years,
2.3%; 75 years, 2.1%; p  0.870) and nonsudden cardiac
death (65 years, 5.3%; 65 to 74 years, 4.7%; 75 years,
5.9%; p  0.378) were observed, while the proportion of
noncardiac death was highest in the oldest group (65
years, 1.1%; 65 to 74 years, 3.0%; 75 years, 3.4%; p 
0.006). The complete results of univariate survival analysis
are listed in Table 3. The responder condition to CRT was
associated with longer survival in the whole series of pa-
tients and in each age group when independently studied
(survival hazard ratio for nonresponder vs responder condi-
tion: 65 years, 0.46, p  0.003; 65 to 74 years, 0.34, p
0.001; 75 years, 0.38, p 0.001; Figure 3). The use of
RT-D was not associated with a significant reduction in
ortality.
Cox multivariate regression analysis showed that age
75 years and the presence of AF were independent pre-
ictors of a worse prognosis, while a higher LVEF and the
Figure 3. Kaplan-Meier analysis of overall survival in each age group, by
CRT responder condition. The favorable effects on prognosis of the con-
dition are evident also in the oldest patients. LV  left ventricular.
Table 4
Clinical predictors of all-cause mortality during follow-up: results of
multivariate Cox regression analysis
Variable HR 95% CI p
Age groups (years)
65 1
65–74 1.17 0.80–1.69 0.420
75 1.57 1.06–2.35 0.026
Men vs women 1.38 0.90–2.12 0.144
Renal failure ( vs ) 1.29 0.75–2.22 0.349
Coronary artery disease ( vs ) 1.18 0.87–1.60 0.281
LVEF (%) 0.96 0.94–0.98 0.001
Permanent AF ( vs ) 1.63 1.16–2.30 0.005
Angiotensin-converting enzyme
inhibitors/angiotensin
receptor blockers ( vs )
0.72 0.52–0.98 0.038
 blockers ( vs ) 0.49 0.35–0.67 0.001
CRT responder ( vs ) 0.37 0.27–0.51 0.001
Abbreviations as in Table 3.se of angiotensin-converting enzyme inhibitors or angio-
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1514 The American Journal of Cardiology (www.ajconline.org)tensin receptor blockers and of  blockers were correlated
with improved survival. Finally, the condition of responder
to CRT was associated with a 63% reduction in the risk for
death (Table 4). Separate multivariate survival analysis
models developed for each age group pointed out that the
protective role of -blocker use and the worse prognosis
ssociated with AF were evident only in patients aged 65
ears.
Device implantation complications were observed in 190
atients (11%). The most frequent event was the dislodg-
ent of 1 of the leads (n  126 [7.1%]). Pocket infection
ith or without skin erosion was observed in 44 patients
2.5%). The only other complication, the stimulation of the
hrenic nerve, was present in the 28 remaining patients
1.6%). No age-related trend was noticed in the incidence of
dverse events (65 years, 10%; 65 to 74 years, 11%; 75
ears, 10%; p  0.596).
iscussion
Our study shows that the use of CRT in the elderly is a
ommon practice in the real world: patients aged 75 years
ccounted for 1/4 of all implanted patients, and no age-
elated differences in the efficacy of the treatment were
bserved. Moreover, the database of the InSync/InSync ICD
talian Registry was made up of one of the largest group of
lderly subjects ever studied, a segment of population usu-
lly excluded in clinical trials.2,3,15 The recent demonstra-
ion, in the Framingham Offspring Cohort, that lower car-
iac performance is associated with accelerated brain
ging16 and that CRT improved neurocognitive measures of
ttention, information processing, and quality of life17 fur-
ther strengthens the geriatric meaning of our results. To
define CRT responders, we adopted a cut-off value of 10%
for the reduction of left ventricular end-systolic volume, as
obtained by Yu et al14 in a younger population. We found
that this criterion was able to identify a proportion of re-
sponders similar to those of other studies (pooled preva-
lence of echocardiographic responders in 15 large studies:
56.9%18) and to predict favorable clinical outcomes inde-
pendent of age. Furthermore, a previous analysis of the
InSync/InSync ICD Italian Registry revealed that an isch-
emic cause of CHF was the only clinical determinant of the
nonresponder condition.12
In the presence of overt CHF, age and gender may
significantly influence medical behavior. In an outpatient
population with LVEF 35%, the Registry to Improve the
Use of Evidence-Based Heart Failure Therapies in the Out-
patient Setting (IMPROVE-HF) showed that older subjects,
particularly older women, were significantly less likely to
receive guideline-recommended CHF therapies.19 The re-
sults of the American Heart Association’s Get With the
Guidelines–Heart Failure (GWTG-HF) program, extending
the observation to devices, further supported this evidence,
demonstrating also that women had a lower probability than
men to receive CRT20 and implantable cardioverter-defi-
rillators.21 In our study, angiotensin-converting enzyme
nhibitors or angiotensin receptor blockers and  blockers
ere significantly underused, particularly at advanced age.
hese findings were confirmed by recent observations ob-ained in a tertiary center of care, which demonstrated theeduced use of  blockers in CRT patients, with a resulting
ncrease of mortality and need for heart transplantation.22
Possible explanations of the underuse of drug therapy in the
elderly may involve factors related to patients (e.g., frailty,
co-morbidities, poor tolerance) or to physicians (e.g., fear of
side effects, lack of awareness of guidelines prescrip-
tions).23 In our study, probably because of the improved
linical status and the certainty that bradycardia could have
ot developed, the 12-month use of  blockers increased in
the 2 oldest segments of population (65 years, 60% vs
62%, p  0.396; 65 to 74 years, 45% vs 53%, p  0.001;
75 years, 37% vs 50%, p 0.001).
Results from the Candesartan in Heart Failure—Assess-
ment of Reduction in Mortality and Morbidity (CHARM)
program,24 then confirmed by a meta-analysis of 7 random-
ized trials and 9 observational studies,25 proved that the
resence of AF determined an increased risk for morbidity
nd mortality in patients with symptomatic heart failure
egardless of baseline LVEF. Moreover, as shown by the
uro Heart Survey on AF, when CHF and AF coexist, the
nderprescription of guidelines-recommended medical ther-
py can be further potentiated.26 Also in our patients, per-
manent AF was associated with increased mortality. In this
regard, Kamath et al27 demonstrated the importance of an
effective biventricular capture to ensure clinical response
from CRT in subjects with permanent AF. In this situation,
there is no atrioventricular synchrony, and effective CRT is
difficult to establish. Atrioventricular junction ablation al-
lows a steady ventricular capture with a favorable impact on
prognosis.28 In our study, in patients with permanent AF,
the execution of atrioventricular junction ablation signifi-
cantly decreased with age (65 years, 46%; 65 to 74 years,
51%; 75 years, 32%; p  0.011). Thus, the risk for a
suboptimal proportion of paced beats in 2/3 of the oldest
patients with AF needs to be considered.
One of the most intriguing aspects of our study is the lack
of statistical significance between CRT-D and survival dur-
ing follow-up. Our findings seem to be in contrast to those
of the Comparison of Medical Therapy, Pacing, and Defi-
brillation in Heart Failure (COMPANION) trial, in which
only CRT-D, and not CRT, proved to have a significant
effect on mortality.15 Our results can be interpreted through
he following assumptions: (1) the increase in mortality in
atients with advanced forms of CHF is due to a progres-
ively higher incidence of the refractory nonarrhythmic
orms of disease29; (2) likewise, in elderly patients with
heart failure, it is possible to observe a similar shift in
mortality causes independent of the LVEF and New York
Heart Association class. In this regard, in the 6,252 subjects
enrolled in the Amiodarone Trialists Meta-Analysis, Krahn
et al30 observed that the sudden cardiac death/overall mor-
tality ratio reduced from 0.50 to 0.26 from age50 years to
age 80 years. Confirming this hypothesis, in the InSync
population, we observed a significant age-related increase
only for noncardiac mortality causes. However, we cannot
rule out that if our length of follow-up had been longer or
the data set dimensions adequately powered, the influence
of CRT-D on survival would have been significant.
Our data are derived from a registry, so we cannot
exclude the presence of some selection bias. In particular,
concerning our elderly patients, the prevalence of co-mor-
22
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1515Heart Failure/CRT in Elderly Patientsbidities and the number of hospitalizations for CHF in the
12 months preceding the study are low, not dissimilar from
what is observed at younger ages. These findings are con-
sistent with the possibility that our oldest subjects were
“significantly healthier” than their counterparts who were
not proposed for CRT. However, the end point of our study,
aiming to assess the existence of age-related differences in
the clinical and instrumental response to CRT, should have
not been influenced by this limitation. The analyzed data
were derived from a multicenter registry. So, despite the
existence of a well-defined protocol and the several meet-
ings that were held among the researchers, we cannot rule
out that data collection was not fully homogenous in the
different laboratories involved in the study. Regarding
echocardiographic evaluation, it was impossible to blind the
operator to the phase of the follow-up in which the patient
was examined. Also in this case, the high degree of intra-
center and intercenter consistency of the results should
exclude the existence of a significant bias.
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